Neurona Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neurona Therapeutics develops interneuron cell therapies derived from human iPSCs to repair dysregulated neural circuits; lead program NRTX-1001 is in Phase 1/2 trials for drug-resistant focal epilepsy;
About
Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Neurona Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.